Fox Run Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Fox Run Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2,925	Closed	-$335K	–	310
2020 Q3	$335K	Sell	2,925 -642	-18%	-$69.3K	0.84%	26
2020 Q2	$400K	Buy	+3,567	New	+$379K	0.53%	41
2020 Q1	–	Sell	-2,344	Closed	-$254K	–	423
2019 Q4	$254K	Sell	2,344 -4,690	-67%	-$502K	0.2%	254
2019 Q3	$689K	Buy	7,034 +2,419	+52%	+$273K	0.63%	9
2019 Q2	$604K	Buy	+4,615	New	+$595K	0.4%	44
2019 Q1	–	Sell	-8,135	Closed	-$792K	–	767
2018 Q4	$792K	Buy	+8,135	New	+$962K	0.42%	25
2018 Q2	–	Sell	-13,562	Closed	-$1.51M	–	993
2018 Q1	$1.51M	Buy	+13,562	New	+$1.62M	0.37%	16
2017 Q4	–	Sell	-8,300	Closed	-$1.16M	–	961
2017 Q3	$1.16M	Buy	8,300 +4,800	+137%	+$652K	0.33%	30
2017 Q2	$426K	Buy	+3,500	New	+$407K	0.15%	280
2016 Q4	–	Sell	-2,600	Closed	-$319K	–	737
2016 Q3	$319K	Buy	+2,600	New	+$335K	0.19%	234

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Fox Run Management's ALXN Position: Q4 2020 in Review

Fox Run Management sold out of Alexion Pharmaceuticals (ALXN) in Q4 2020, closing a stake of 2,925 shares — an estimated $335K sold.

Fox Run Management first reported a position in ALXN in Q3 2016 and held it in 10 quarters. The position peaked at $1.51M in Q1 2018. 827 funds tracked by Wall St. Rank hold ALXN as of Q4 2020.

Fox Run Management reported no remaining Alexion Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Fox Run Management sold 2,925 Alexion Pharmaceuticals shares in Q4 2020, an estimated $335K.
Fox Run Management first reported a position in Alexion Pharmaceuticals in Q3 2016 and held it in 10 quarters.
Fox Run Management's Alexion Pharmaceuticals position peaked at $1.51M in Q1 2018.
827 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2020.

Based on Fox Run Management's 13F filing for Q4 2020, filed 8 Feb 2021.